Australian-based pharmaceutical and medical technologies business, LINK  Healthcare today announced its expansion into the African market via South Africa’s Equity Pharma Group.

According to a statement released by the pharmaceutical company, the expansion was made possible with the completed merger and acquisition agreement with Equity Pharma Group; a strong brand in Southern Africa with focus on specialty medicines, specific generic medicines (such as HIV medicines) and specialist medical technology products.

Executive Chairman of LINK Healthcare, John Bacon said, “This acquisition is particularly pleasing because South Africa’s pharmaceutical sector is increasingly being supported by government with strong growth anticipated for the foreseeable future.”

Mr. Bacon said, “We are delighted to have Equity … incorporated into our group and expect to sign several agreements in the coming months to expand the distribution of existing products across the company’s whole footprint.”

The LINK group now controls advanced regional distribution facilities in Australia, South Africa and Singapore with satellite offices in Japan, New Zealand and Hong Kong.

LINK Healthcare is a privately-owned specialist pharmaceutical and medical technologies business, with an extensive range of prescription pharmaceuticals in essential therapeutic areas. Its business model is focused on marketing specialist prescription pharmaceutical and medical technology products obtained by acquisition from multinationals or in-licensing from mid-sized innovative companies.

The company provides exceptional sales and marketing infrastructure and has partnered with blue chip pharmaceutical companies from around the world, allowing the company to offer a unique and substantial portfolio of ‘medicine that matters.


Elsewhere on Ventures

Triangle arrow